Pamela Samson1, Traves D Crabtree1, Cliff G Robinson2, Daniel Morgensztern3, Stephen Broderick4, A Sasha Krupnick1, Daniel Kreisel1, G Alexander Patterson1, Bryan Meyers1, Varun Puri5. 1. Division of Cardiothoracic Surgery, Washington University School of Medicine, St. Louis, Missouri. 2. Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri. 3. Division of Medical Oncology, Washington University School of Medicine, St. Louis, Missouri. 4. Division of Cardiothoracic Surgery, St. Luke's Hospital, Chesterfield, Missouri. 5. Division of Cardiothoracic Surgery, Washington University School of Medicine, St. Louis, Missouri. Electronic address: puriv@wudosis.wustl.edu.
Abstract
BACKGROUND: Induction therapy leads to significant improvement in survival for selected patients with stage IIIA non-small cell lung cancer. The ideal time interval between induction therapy and surgery remains unknown. METHODS: Clinical stage IIIA non-small cell lung cancer patients receiving induction therapy and surgery were identified in the National Cancer Database. Delayed surgery was defined as greater than or equal to 3 months after starting induction therapy. A logistic regression model identified variables associated with delayed surgery. Cox proportional hazards modeling and Kaplan-Meier analysis were performed to evaluate variables independently associated with overall survival. RESULTS: From 2006 to 2010, 1,529 of 2,380 (64.2%) received delayed surgery. Delayed surgery patients were older (61.2 ± 10.0 years versus 60.3 ± 9.2; p = 0.03), more likely to be non-white (12.4% versus 9.7%; p = 0.046), and less likely to have private insurance (50% versus 58.2%; p = 0.002). Delayed surgery patients were also more likely to have a sublobar resection (6.3% versus 2.9%). On multivariate analysis, age greater than 68 years (odds ratio [OR], 1.37; 95% confidence interval [CI], 1.1 to 1.7) was associated with delayed surgery, whereas white race (OR, 0.75; 95% CI, 0.57 to 0.99) and private insurance status (OR, 0.82; 95% CI, 0.68 to 0.99) were associated with early surgery. Delayed surgery was associated with higher risk of long-term mortality (hazard ratio, 1.25; 95% CI, 1.07 to 1.47). CONCLUSIONS: Delayed surgery after induction therapy for stage IIIA lung cancer is associated with shorter survival, and is influenced by both social and physiologic factors. Prospective work is needed to further characterize the relationship between patient comorbidities and functional status with receipt of timely surgery.
BACKGROUND: Induction therapy leads to significant improvement in survival for selected patients with stage IIIA non-small cell lung cancer. The ideal time interval between induction therapy and surgery remains unknown. METHODS: Clinical stage IIIA non-small cell lung cancerpatients receiving induction therapy and surgery were identified in the National Cancer Database. Delayed surgery was defined as greater than or equal to 3 months after starting induction therapy. A logistic regression model identified variables associated with delayed surgery. Cox proportional hazards modeling and Kaplan-Meier analysis were performed to evaluate variables independently associated with overall survival. RESULTS: From 2006 to 2010, 1,529 of 2,380 (64.2%) received delayed surgery. Delayed surgery patients were older (61.2 ± 10.0 years versus 60.3 ± 9.2; p = 0.03), more likely to be non-white (12.4% versus 9.7%; p = 0.046), and less likely to have private insurance (50% versus 58.2%; p = 0.002). Delayed surgery patients were also more likely to have a sublobar resection (6.3% versus 2.9%). On multivariate analysis, age greater than 68 years (odds ratio [OR], 1.37; 95% confidence interval [CI], 1.1 to 1.7) was associated with delayed surgery, whereas white race (OR, 0.75; 95% CI, 0.57 to 0.99) and private insurance status (OR, 0.82; 95% CI, 0.68 to 0.99) were associated with early surgery. Delayed surgery was associated with higher risk of long-term mortality (hazard ratio, 1.25; 95% CI, 1.07 to 1.47). CONCLUSIONS: Delayed surgery after induction therapy for stage IIIA lung cancer is associated with shorter survival, and is influenced by both social and physiologic factors. Prospective work is needed to further characterize the relationship between patient comorbidities and functional status with receipt of timely surgery.
Authors: Michael Thomas; Christian Rübe; Petra Hoffknecht; Hans N Macha; Lutz Freitag; Albert Linder; Norman Willich; Michael Hamm; Gerhard W Sybrecht; Dieter Ukena; Karl-Matthias Deppermann; Cornelia Dröge; Dorothea Riesenbeck; Achim Heinecke; Cristina Sauerland; Klaus Junker; Wolfgang E Berdel; Michael Semik Journal: Lancet Oncol Date: 2008-06-24 Impact factor: 41.316
Authors: Jan P van Meerbeeck; Gijs W P M Kramer; Paul E Y Van Schil; Catherine Legrand; Egbert F Smit; Franz Schramel; Vivianne C Tjan-Heijnen; Bonne Biesma; Channa Debruyne; Nico van Zandwijk; Ted A W Splinter; Giuseppe Giaccone Journal: J Natl Cancer Inst Date: 2007-03-21 Impact factor: 13.506
Authors: Ho Yun Lee; Hyun Ju Lee; Young Tae Kim; Chang Hyun Kang; Bo Gun Jang; Doo Hyun Chung; Jin Mo Goo; Chang Min Park; Chang Hyun Lee; Keon Wook Kang Journal: J Thorac Oncol Date: 2010-04 Impact factor: 15.609
Authors: Kathy S Albain; R Suzanne Swann; Valerie W Rusch; Andrew T Turrisi; Frances A Shepherd; Colum Smith; Yuhchyau Chen; Robert B Livingston; Richard H Feins; David R Gandara; Willard A Fry; Gail Darling; David H Johnson; Mark R Green; Robert C Miller; Joanne Ley; Willliam T Sause; James D Cox Journal: Lancet Date: 2009-07-24 Impact factor: 79.321
Authors: Aalok P Patel; Traves D Crabtree; Jennifer M Bell; Tracey J Guthrie; Clifford G Robinson; Daniel Morgensztern; Graham A Colditz; Daniel Kreisel; A Sasha Krupnick; Jeffrey D Bradley; G Alexander Patterson; Bryan F Meyers; Varun Puri Journal: J Thorac Oncol Date: 2014-05 Impact factor: 15.609
Authors: K S Albain; V W Rusch; J J Crowley; T W Rice; A T Turrisi; J K Weick; V A Lonchyna; C A Presant; R J McKenna; D R Gandara Journal: J Clin Oncol Date: 1995-08 Impact factor: 44.544
Authors: Mara Antonoff; Leah Backhus; Daniel J Boffa; Stephen R Broderick; Lisa M Brown; Phillip Carrott; James M Clark; David Cooke; Elizabeth David; Matt Facktor; Farhood Farjah; Eric Grogan; James Isbell; David R Jones; Biniam Kidane; Anthony W Kim; Shaf Keshavjee; Seth Krantz; Natalie Lui; Linda Martin; Robert A Meguid; Shari L Meyerson; Tim Mullett; Heidi Nelson; David D Odell; Joseph D Phillips; Varun Puri; Valerie Rusch; Lawrence Shulman; Thomas K Varghese; Elliot Wakeam; Douglas E Wood Journal: Ann Thorac Surg Date: 2020-04-09 Impact factor: 4.330
Authors: Mara Antonoff; Leah Backhus; Daniel J Boffa; Stephen R Broderick; Lisa M Brown; Phillip Carrott; James M Clark; David Cooke; Elizabeth David; Matt Facktor; Farhood Farjah; Eric Grogan; James Isbell; David R Jones; Biniam Kidane; Anthony W Kim; Shaf Keshavjee; Seth Krantz; Natalie Lui; Linda Martin; Robert A Meguid; Shari L Meyerson; Tim Mullett; Heidi Nelson; David D Odell; Joseph D Phillips; Varun Puri; Valerie Rusch; Lawrence Shulman; Thomas K Varghese; Elliot Wakeam; Douglas E Wood Journal: J Thorac Cardiovasc Surg Date: 2020-04-09 Impact factor: 5.209
Authors: Daniel J Boffa; Benjamin L Judson; Kevin G Billingsley; Erin Del Rossi; Kasey Hindinger; Samantha Walters; Theresa Ermer; Elena Ratner; Marci R Mitchell; Maxwell S Laurans; Dirk C Johnson; Peter S Yoo; John M Morton; Holly B Zurich; Kimberly Davis; Nita Ahuja Journal: Ann Surg Date: 2020-12 Impact factor: 12.969
Authors: Chris Dickhoff; Suresh Senan; Famke L Schneiders; Joris Veltman; Sayed Hashemi; Johannes M A Daniels; Marieke Fransen; David J Heineman; Teodora Radonic; Peter M van de Ven; Imke H Bartelink; Lilian J Meijboom; Juan J Garcia-Vallejo; Daniela E Oprea-Lager; Tanja D de Gruijl; Idris Bahce Journal: BMC Cancer Date: 2020-08-14 Impact factor: 4.430
Authors: Brendan T Heiden; Daniel B Eaton; Kathryn E Engelhardt; Su-Hsin Chang; Yan Yan; Mayank R Patel; Daniel Kreisel; Ruben G Nava; Bryan F Meyers; Benjamin D Kozower; Varun Puri Journal: JAMA Netw Open Date: 2021-05-03